Moffitt Medical GroupSenior Adult Oncology Program 12902 Usf Magnolia Dr, Tampa, FL 33612 (813)7456769 (phone), (813)7453730 (fax)
Education:
Medical School New York University School of Medicine Graduated: 1980
Procedures:
Chemotherapy
Conditions:
Melanoma Rectal, Abdomen, Small Intestines, or Colon Cancer Abdominal Hernia Acute Pancreatitis Acute Renal Failure
Languages:
English Spanish
Description:
Dr. Weber graduated from the New York University School of Medicine in 1980. He works in Tampa, FL and specializes in Medical Oncology. Dr. Weber is affiliated with Moffitt Cancer Center.
Dr. Weber graduated from the Pennsylvania State University College of Medicine in 1993. He works in Ephrata, PA and specializes in Family Medicine. Dr. Weber is affiliated with WellSpan Ephrata Community Hospital.
Mr. Weber works in Raleigh, NC and 1 other location and specializes in Pain Management. Mr. Weber is affiliated with Duke Raleigh Hospital and Wakemed Raleigh Campus.
- Armonk NY, US Jeffrey Kurt Weber - Brooklyn NY, US Sugato Bagchi - White Plains NY, US Wendy Dawn Cornell - Warren NJ, US
International Classification:
G16B 15/30 G06N 3/04 G06N 3/08
Abstract:
A system and method for structure-based, small molecule activity prediction using binding mode prediction information. Binding scores between ligands and target molecules, (e.g. proteins, RNA, DNA, lipids, sugars) are first generated using molecular docking. A first machine learned deep neural network (DNN) model is developed using data representing the molecular ligand-target pair 3D structures and docking features to predict binding modes. Using transfer learning, weights of layers learned in the first machine learned model are used as weights in layers of a second machine learned DNN model used to more accurately improve the performance of activity prediction of the second machine learned model. For a target newly paired ligand-target complex, the method further implements a binding mode selector for selecting one or more particular binding poses for input to the activity prediction model for use in activity mode prediction of an activity of the target paired ligand-protein complex.
Target Molecule-Ligand Binding Mode Prediction Combining Deep Learning-Based Informatics With Molecular Docking
A computer-implemented method is described. The method includes generating, by a ligand bond graph generator, a first graph based on bond connectivity within a ligand molecule that is specified as input. The method further includes generating, by a ligand-protein graph generator, a second graph based on a contact map of the ligand molecule and a target molecule that is specified as another input. The method further includes receiving docking prediction metrics for the ligand molecule and the target molecule. The method further includes inputting, to a deep neural network, as input features, the first graph, the second graph, and the docking prediction metrics. The method further includes determining, using the deep neural network, a binding mode prediction that characterizes a set of potential interactions between the ligand molecule and the target molecule.
For covid-19 patients, cytokine storms are a major reason that some require intensive care and ventilation, said Jeffrey Weber, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center.
Date: Apr 15, 2020
Category: More news
Source: Google
New clinical trial might change the standard treatment for melanoma
Results like this will change how we practice medicine, said Jeffrey Weber, a professor of medicine at NYU Langone School of Medicine, who presented the findings at the annual meeting of the European Society for Medical Oncology in Madrid. The results were published simultaneously online in the Ne
"This is clearly an outstanding science result that sets the scene for the further development of the test to quantify [immune biomarkers] in different malignancies," said Dr. Jeffrey Weber, an immunologist and oncologist at the Moffitt Cancer Center in Tampa, Fla., who was
"It's the first in a series of targeted drugs, meaning it's a drug that targets a specific mutation in about half of all melanomas that begin on the skin," said Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center at the H. Lee Moffitt Cancer Center. "It's really imp
Date: Aug 21, 2011
Category: Health
Source: Google
New melanoma drug had trial run at Moffitt Cancer Center
Dr. Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt, was an investigator on a Phase II student that enrolled 132 patients. The study showed that vemurafenib (pronounced vem-yoo-RAF-en-ib) shrank tumors in 52 percent of trial participants, and participa
University of Louisville - Electrical Engineering, Atherton High School
About:
I now own my own company Frozen Mercury Productions, I hope it's the start of something amazing. I am a jack of all trades I know something about everything, and am willing to share all my knowled...
Tagline:
Jeffrey Arra Weber
Jeffrey Weber
Work:
Booz Allen Hamilton
Education:
Virginia Polytechnic Institute and State University
Jeffrey Weber
Education:
McCluer North High School
Relationship:
Married
Jeffrey Weber
Tagline:
G-Code
Jeffrey Weber
Jeffrey Weber
Jeffrey Weber
Jeffrey Weber
Youtube
Cancer Revealed: How the Immune System Sees a...
On June 16, 2015, Jeffrey S. Weber, M.D., Ph.D., discussed the cancer ...
Duration:
1h 2m 36s
Meet Oncologist Dr. Jeffrey Weber
NYU Langone oncologist Dr. Jeffrey Weber is a specialist in melanoma m...
Duration:
2m 21s
Dr Jeffrey Weber explains his approach to imm...
Drs Jeffrey Weber and Khalid Jazieh discuss immunotherapy-in... colit...
Duration:
10m 9s
How to manage chronic non-cutaneous immune-re...
Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, disc...
Duration:
5m 25s
Jeffrey Weber Explains Organ-Specific Side Ef...
Jeffrey Weber, MD, PhD, from NYU Langone Perlmutter Cancer Center expl...
Duration:
1m 51s
Dr. Jeffrey Weber on Optimal Therapy Sequence...
Jeffrey S. Weber, MD, PhD, the director of the Donald A. Adam Comprehe...